Liana, diagnosed with hATTR amyloidosis
and her daughter Gabriella (Brazil)

Our Company

OUR PATIENT ACCESS PHILOSOPHY

Keeping Patients at the Center of Everything We Do

Throughout our 20+ year journey in developing RNAi therapeutics, we have remained focused on keeping patients at the center of everything we do. Beyond accepting the challenges of scientific discovery and development, we believe that we are accountable for ensuring that patients who can benefit from our medicines have access to them.

Our Patient Access Philosophy, established in 2017 – before our first medicine was approved – continues to guide us, holding us accountable for ensuring that access and outcomes align with the value our therapies bring to patients.

At Alnylam, we know that medical and scientific innovation are only worthwhile if the people who can benefit from life-changing therapies have access to them. Despite living in an age of medicinal breakthroughs, patients are too often unable to receive the treatment they need due to their location, their insurance, or other obstacles. We believe it is our responsibility to work with partners around the world to ensure our drugs are accessible and affordable to all, because no patient should have to wait for hope. — Yvonne Greenstreet, MD, MBA, CEO of Alnylam

Our Patient Access Philosophy & Progress
Fact Sheet

Learn more about our progress in 2024.

DOWNLOAD PDF

>

0

%

U.S. residents with confirmed access to one of our therapies

0

countries where patients can access our therapies by way of direct or distributor infrastructure

0

+

patients supported by Alnylam Assist in 2024

Additional Information

Alnylam Assist®

Since Alnylam’s first commercial launch in 2018, our comprehensive, in-house ecosystem, Alnylam Assist®, has supported patients throughout their entire treatment journey. Alnylam Assist® is primarily staffed by Alnylam employees solely dedicated to supporting patients and providers throughout the journey with an Alnylam therapeutic. This model has enabled our team to develop a deep understanding of the patient journey so that they can expertly manage issues related to treatment initiation, access and reimbursement, and offer financial assistance to provide best-in-class patient support services.

VISIT SITE ›

Alnylam Act®

Alnylam Act® is a sponsored, no-charge, third-party genetic testing and counseling program for people in the U.S. and Canada with a family history or suspected diagnosis of certain genetic conditions. The Alnylam Act program was developed to provide genetic testing and counseling services to people and their families so that they may make more informed decisions about their health. Through the Alnylam Act program, genetic testing and counseling is offered at no charge to individuals who meet the eligibility criteria.

VISIT SITE ›

Alnylam’s Patient Access Philosophy Principles

Sustainable Value and Significant Impact

We believe it is our responsibility to push the boundaries of scientific discovery, clinical development, and delivery to fuel significant, sustainable patient impact.

We make decisions for as many people who can benefit from the potential of our medicines.
We believe we have an obligation to commit resources that promote diversity of clinical trials, ensure equitable access, and empower individuals with choice.

We act with purposeful urgency to expand our geographic reach and enable sustainable access pathways.

Connecting to Achieve Better Outcomes

We believe that together with partners in the healthcare ecosystem, we can reduce barriers to our medicines to improve outcomes for all stakeholders in the patient journey – most importantly, for the patients who may benefit from them.

We believe biopharmaceutical companies must address access and improve outcomes from the time of drug discovery.
We recognize that a patient’s ability to access and afford our medicines is complex, and we commit to continuing our legacy of value-centric solutions.

We seek to remove barriers within our control to enable patients to receive care in convenient settings.

Proactive and Accountable

We believe that biopharmaceutical companies play a critical role in the patient’s journey to accessing innovative therapeutic options and should be accountable for progress.

We aim to create compliant solutions that are designed to empower patients to feel confident throughout their treatment journey.
We advocate for policies, technology and evidence to promote innovation and reduce the time for approved treatments to reach patients.

We partner with others for the sake of science and the good of patients, committed to the continuous evolution that began before we launched the world’s first RNAi therapeutic and will endure for as long as we are Alnylam.

Our Progress:

2024 Approach to Access and Affordability Fact Sheet

DOWNLOAD

(Format: PDF)

Corporate Social Responsibility Report 2024